Features of 16,749 hospitalised UK patients with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol

2020 bioRxiv (Cold Spring Harbor Laboratory) 392 citations

Abstract

Structured abstract Objective To characterize the clinical features of patients with severe COVID-19 in the UK. Design Prospective observational cohort study with rapid data gathering and near real-time analysis, using a pre-approved questionnaire adopted by the WHO. Setting 166 UK hospitals between 6 th February and 18 th April 2020. Participants 16,749 people with COVID-19. Interventions No interventions were performed, but with consent samples were taken for research purposes. Many participants were co-enrolled in other interventional studies and clinical trials. Results The median age was 72 years [IQR 57, 82; range 0, 104], the median duration of symptoms before admission was 4 days [IQR 1,8] and the median duration of hospital stay was 7 days [IQR 4,12]. The commonest comorbidities were chronic cardiac disease (29%), uncomplicated diabetes (19%), non-asthmatic chronic pulmonary disease (19%) and asthma (14%); 47% had no documented reported comorbidity. Increased age and comorbidities including obesity were associated with a higher probability of mortality. Distinct clusters of symptoms were found: 1. respiratory (cough, sputum, sore throat, runny nose, ear pain, wheeze, and chest pain); 2. systemic (myalgia, joint pain and fatigue); 3. enteric (abdominal pain, vomiting and diarrhoea). Overall, 49% of patients were discharged alive, 33% have died and 17% continued to receive care at date of reporting. 17% required admission to High Dependency or Intensive Care Units; of these, 31% were discharged alive, 45% died and 24% continued to receive care at the reporting date. Of those receiving mechanical ventilation, 20% were discharged alive, 53% died and 27% remained in hospital. Conclusions We present the largest detailed description of COVID-19 in Europe, demonstrating the importance of pandemic preparedness and the need to maintain readiness to launch research studies in response to outbreaks. Trial documentation Available at https://isaric4c.net/protocols . Ethical approval in England and Wales (13/SC/0149), and Scotland (20/SS/0028). ISRCTN (pending).

Keywords

MedicineSore throatmyalgiaComorbidityWheezeAsthmaVomitingAbdominal painChest painCOPDInternal medicinePediatricsPhysical therapySurgery

Affiliated Institutions

Related Publications

Publication Info

Year
2020
Type
preprint
Citations
392
Access
Closed

External Links

Social Impact

Social media, news, blog, policy document mentions

Citation Metrics

392
OpenAlex

Cite This

AB Docherty, Ewen M Harrison, CA Green et al. (2020). Features of 16,749 hospitalised UK patients with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol. bioRxiv (Cold Spring Harbor Laboratory) . https://doi.org/10.1101/2020.04.23.20076042

Identifiers

DOI
10.1101/2020.04.23.20076042